Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BDNF | P23560 | 3/20 | 0.42 |
| ▸ | PTN | P21246 | 2/20 | 0.42 |
| ▸ | MDK | P21741 | 2/20 | 0.42 |
| ▸ | MAG | P20916 | 2/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695250 | 0.93 | MAPK1 (0.50) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL21650603 | 0.89 | ALDH1A1 (0.47) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL18098580 | 0.89 | ALDH1A1 (0.47) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL19509535 | 0.88 | MAPK1 (0.46) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL12878533 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL8062325 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL29533003 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL30055691 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL29472159 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL19864355 | 0.85 | MAPK1 (0.59) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193116-A1 | CROSS-LINKED HYALURONIC ACIDS AND COMBINATIONS WITH PRP/BMC | REGEN LAB SA (CH) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193116-A1 | CROSS-LINKED HYALURONIC ACIDS AND COMBINATIONS WITH PRP/BMC | IL2, CD44, TNF | MAPK1 1052/4885LGALS3 3498/4885LGALS8 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.